2. Cell Cycle/DNA Damage Epigenetics Apoptosis
  3. Sirtuin Apoptosis
  4. Ganoderic acid D

Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis.

For research use only. We do not sell to patients.

Ganoderic acid D Chemical Structure

Ganoderic acid D Chemical Structure

CAS No. : 108340-60-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 143 In-stock
Solution
10 mM * 1 mL in DMSO USD 143 In-stock
Solid
1 mg USD 50 In-stock
5 mg USD 130 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ganoderic acid D:

Ganoderic acid D Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Ganoderic acid D

View All Sirtuin Isoform Specific Products:

View All Isoforms
Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells[1]. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis[2].

IC50 & Target[1]

SIRT3

 

Cellular Effect
Cell Line Type Value Description References
BV-2 IC50
10.86 μM
Compound: 14
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay
[PMID: 27335254]
HepG2 IC50
22.9 μM
Compound: 12
Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 24974349]
In Vitro

Ganoderic acid D can inhibit the growth of numerous cancer cell lines and it inhibits HeLa human cervical carcinoma cells with an IC50 of 17.3 mM[2]. Ganoderic acid D (1-50 μM; 24-72 hours) reduces the cell survival rate in a dose- and time-dependent manner[2].
Ganoderic acid D (10, 50 μM; 24, 48 hours) induces G2/M phase arrest[2].
Ganoderic acid D (10, 50 μM; 24, 48 hours) induces a morphological change typical of apoptosis in HeLa cells[2].
Ganoderic acid D (10 μM; 48 hours) up-regulates 14-3-3E and PRDX3[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ganoderic acid D Related Antibodies

Cell Viability Assay[2]

Cell Line: HeLa human cervical carcinoma cell line (CCL-2)
Concentration: 1, 5, 10, 20, 50 μM
Incubation Time: 24, 48, 72 hours
Result: Reduced the cell survival rate in a dose- and time-dependent manner and had an IC50 value of 17.3 μM for 48 hours treatment.

Cell Cycle Analysis[2]

Cell Line: HeLa human cervical carcinoma cell line (CCL-2)
Concentration: 10, 50 μM
Incubation Time: 24, 48 hours
Result: Induced G2/M phase arrest.
Displayed a cell cycle profile with an elevated G2/M cell population after 24-h treatment with 10 μM.

Apoptosis Analysis[2]

Cell Line: HeLa human cervical carcinoma cell line (CCL-2)
Concentration: 10, 50 μM
Incubation Time: 48 hours
Result: Induced a morphological change typical of apoptosis in HeLa cells.

Western Blot Analysis[2]

Cell Line: HeLa human cervical carcinoma cell line (CCL-2)
Concentration: 10 μM
Incubation Time: 48 hours
Result: Up-regulated 14-3-3E and PRDX3.
Molecular Weight

514.65

Formula

C30H42O7
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1(C)C(CC[C@]2(C)C3=C([C@@]4(C(C[C@@H]([C@]4(CC3=O)C)[C@H](C)CC(CC(C)C(O)=O)=O)=O)C)[C@@H](O)C[C@@]12[H])=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (194.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9431 mL 9.7153 mL 19.4307 mL
5 mM 0.3886 mL 1.9431 mL 3.8861 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.81%

SDS (393 KB)

COA (254 KB) HNMR (289 KB) LCMS (258 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9431 mL 9.7153 mL 19.4307 mL 48.5767 mL
5 mM 0.3886 mL 1.9431 mL 3.8861 mL 9.7153 mL
10 mM 0.1943 mL 0.9715 mL 1.9431 mL 4.8577 mL
15 mM 0.1295 mL 0.6477 mL 1.2954 mL 3.2384 mL
20 mM 0.0972 mL 0.4858 mL 0.9715 mL 2.4288 mL
25 mM 0.0777 mL 0.3886 mL 0.7772 mL 1.9431 mL
30 mM 0.0648 mL 0.3238 mL 0.6477 mL 1.6192 mL
40 mM 0.0486 mL 0.2429 mL 0.4858 mL 1.2144 mL
50 mM 0.0389 mL 0.1943 mL 0.3886 mL 0.9715 mL
60 mM 0.0324 mL 0.1619 mL 0.3238 mL 0.8096 mL
80 mM 0.0243 mL 0.1214 mL 0.2429 mL 0.6072 mL
100 mM 0.0194 mL 0.0972 mL 0.1943 mL 0.4858 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ganoderic acid D Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ganoderic acid D108340-60-9SirtuinApoptosisoxygenatedtetracyclictriterpenoiddeacetylatedcyclophilinDCypDcoloncancerHeLahumancervicalcarcinomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ganoderic acid D
Cat. No.:
HY-N1511
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.